Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

TUSTIN, Calif., July 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced financial results for the fourth quarter and fiscal year (FY) 2009 ended April 30, 2009. Total revenues for the fourth quarter of FY 2009 increased to $7,867,000, compared to $901,000 for the comparable quarter in FY 2008. Total revenues for the 2009 fiscal year increased approximately 200% from $6,093,000 in FY 2008 to $18,151,000 in FY 2009, primarily from increased contract manufacturing revenues generated by Avid Bioservices, the company's wholly owned subsidiary, and increased revenues derived from the company's R&D contract with the federal government.

Avid generated manufacturing revenues of $5,009,000 for the fourth quarter of FY 2009, compared to $751,000 for the comparable prior year quarter, while full year FY 2009 manufacturing revenues more than doubled to $12,963,000, up from $5,897,000 in FY 2008. The increase in Avid revenues reflects increased manufacturing services provided to third-party customers during the quarter and the full fiscal year. In addition to manufacturing revenues, during FY 2009 Peregrine generated revenues from services provided under its government contract with the U.S. Defense Threat Reduction Agency (DTRA) to evaluate bavituximab as a potential broad spectrum treatment for viral hemorrhagic fever infections. Government contract revenues were $2,683,000 for the fourth quarter of FY 2009 and $5,013,000 for the 2009 fiscal year. Peregrine's work under the DTRA contract began during FY 2009, so there are no comparable figures for FY 2008.

Total costs and expenses in the fourth quarter of FY 2009 were $11,239,000, compared to $7,198,000 in the fourth quarter of FY 2008. Increa
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Mutare Health, a ... nationally-renowned Gastroenterologist Lawrence Kosinski, MD, MBA, AGAF, to ... Kosinski brings a unique combination of medical experience, ... Mutare Health team as it continues ... and quality of care in the healthcare environment. ...
(Date:4/20/2015)... 20, 2015 Novatus, a leading ... expanded its service level to the growing European ... Amsterdam and Paris. After a rigorous review ... levels of resilience, security and operational expertise, and ... for Novatus as we expand our footprint and ...
(Date:4/20/2015)... York (PRWEB) April 20, 2015 ... representing the U.S. health insurance industry, is seeking ... of the recent controversy involving surgical tools called ... to U.S. Senator Robert Casey (D-PA) dated April ... surrounding uterine morcellation point to “serious gaps in ...
(Date:4/20/2015)... 1% for the Planet , one of ... Kate Williams, the network’s Director of Partnerships, will step into ... has been part of 1% for the Planet since early ... the Northern Forest Canoe Trail, a 1% for the Planet ... stewardship of and advocacy for the outdoors, a commitment which ...
(Date:4/20/2015)... Grateful Dead originally formed in 1965 in ... The group was more than just about rock music. They ... rock, country, and other genres to put together their greatest ... group was inducted into the Rock and Roll Hall of ... 35 million records worldwide. This year marks the 50th ...
Breaking Medicine News(10 mins):Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 3Health News:Novatus Expands into European Data Centers 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 4Health News:1% for the Planet Announces New CEO 2Health News:1% for the Planet Announces New CEO 3Health News:Grateful Dead Tickets at Levi’s Stadium in Santa Clara: Ticket Down Slashes Grateful Dead Tickets in Santa Clara @ Levi’s Stadium for "Fare Thee Well" 50th Anniversary 2
... an AIDS drug and a heart medicine, and entered into ... more people can be treated. ,The negotiation panel ... first talks with US firm Abbott to discuss a price ... head of the department of disease control, said the firm ...
... the light-sensitive protein found in many marine bacteria. ... National Laboratory (Berkeley Lab) and the University of California ... respire oxygen is impaired, bacterium equipped with proteorhodopsin will ... processes. ,“Our research shows that proteorhodopsin ...
... accurately identify colorectal cancer patients with a specific type ... patient has an inherited// form of the disease or ... ,Some people with colorectal cancer have defects in ... these mutations by looking for a gene marker called ...
... solved a decades-old cancer mystery. "We not only found ... master switch for a tumor suppressive network that means ... said CSHL Associate Professor Alea Mills, Ph.D. The study, ... of Cell. ,Specifically, Mills' discovery identifies CHD5, ...
... cases of malaria due to Plasmodium falciparum on the island ... reported cases, 264 have occurred in Kingston// , 12 in ... There have been no reported deaths due to malaria. ... the WHO Regional Office for the Americas coordinated by the ...
... IV study of KADIAN ? (morphine sulfate extended-release) Capsules ... leading pharmaceutical company. It reveals that the pharmacokinetics// of ... consumption of alcohol. ,Results of this pharmacokinetic ... by the U.S. Food and Drug Administration (FDA) to ...
Cached Medicine News:Health News:Thailand Backs Off Threat to Break Drug Patents 2Health News:Shedding New Light on Proteorhodopsin 2Health News:Scientists Discover New Gene 2Health News:KADIAN Efficacy Not Affected by Alcohol Consumption 2
(Date:4/20/2015)... April 20, 2015 Research published today in ... Sciences (PNAS) demonstrates that technology invented by ... Casey Eye Institute can improve the clinical ... coherence tomography (OCT) angiography could largely replace current ... OHSU researchers found that OCT angiography ...
(Date:4/20/2015)... Mass. , April 20, 2015 ... and final clinical results for the Phase 1 ... in HER2-positive metastatic breast cancer.  The results were ... clinical trials plenary oral session at the 2015 ... in Philadelphia, PA. Data ...
(Date:4/20/2015)... YORK , April 20, 2015 This report ... Instruments in US$ Million by the following Product Segments: Sphygmomanometers ... and Blood Pressure Transducers. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates and forecasts ...
Breaking Medicine Technology:Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5World Blood Pressure Monitoring and Measurement Instruments Industry 2World Blood Pressure Monitoring and Measurement Instruments Industry 3World Blood Pressure Monitoring and Measurement Instruments Industry 4World Blood Pressure Monitoring and Measurement Instruments Industry 5World Blood Pressure Monitoring and Measurement Instruments Industry 6World Blood Pressure Monitoring and Measurement Instruments Industry 7World Blood Pressure Monitoring and Measurement Instruments Industry 8World Blood Pressure Monitoring and Measurement Instruments Industry 9World Blood Pressure Monitoring and Measurement Instruments Industry 10World Blood Pressure Monitoring and Measurement Instruments Industry 11World Blood Pressure Monitoring and Measurement Instruments Industry 12World Blood Pressure Monitoring and Measurement Instruments Industry 13World Blood Pressure Monitoring and Measurement Instruments Industry 14World Blood Pressure Monitoring and Measurement Instruments Industry 15World Blood Pressure Monitoring and Measurement Instruments Industry 16World Blood Pressure Monitoring and Measurement Instruments Industry 17World Blood Pressure Monitoring and Measurement Instruments Industry 18World Blood Pressure Monitoring and Measurement Instruments Industry 19World Blood Pressure Monitoring and Measurement Instruments Industry 20World Blood Pressure Monitoring and Measurement Instruments Industry 21World Blood Pressure Monitoring and Measurement Instruments Industry 22World Blood Pressure Monitoring and Measurement Instruments Industry 23World Blood Pressure Monitoring and Measurement Instruments Industry 24World Blood Pressure Monitoring and Measurement Instruments Industry 25World Blood Pressure Monitoring and Measurement Instruments Industry 26World Blood Pressure Monitoring and Measurement Instruments Industry 27World Blood Pressure Monitoring and Measurement Instruments Industry 28
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... 2010.  Third quarter 2010 net revenues were $42.0 million, ... 2009.  Excluding the recognition of one-time license revenue in ... 44%.  Net loss for the third quarter ended September ...
... 2, 2010 Cannabis Science, Inc. (OTC Bulletin Board: ... cannabis products, is pleased to announce to its shareholders and ... decisions and processes regarding the new class of common shares. ... 1 for 10 new share dividend payment for shareholders of ...
Cached Medicine Technology:ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 2ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 3ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 4ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 5ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 6ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 7ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 8ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 9ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 10Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 2Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 3
Bio-Rad's Liquichek™ D-dimer Control provides the laboratory with a liquid, trilevel, human plasma based control for the monitoring of D-dimer testing on most automated coagulation, chemistry a...
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek Diabetes Control is a human whole blood based product used to monitor hemoglobin fractions associated with diabetes, including Hemoglobins A1, A1C, F and Total Glycated Hemoglobin....
... Liquichek Qualitative Urine Toxicology Control is a ... rapid urine drug screen panels, including Point ... test kits like Bio-Rad TOX/See, Biosite Triage ... qualitative results (+/) for popular kits and ...
Medicine Products: